

Ready to start planning your care? Call us at [800-525-2225](tel:800-525-2225) to make an appointment.

×



Memorial Sloan Kettering
Cancer Center

[Find an MSK Doctor or Cancer Specialist](#)

[Make an Appointment](#)

[Patient & Caregiver Resources & Treatment](#)

[Refer a Patient](#)

ABOUT US

[Our mission, vision & core values](#)

[Leadership](#)

[History](#)

[Equality, diversity & inclusion](#)

[Annual report](#)

[Give to MSK](#)

Gastrointestinal Malignancies

New Chemotherapies

Esophageal and Gastric Cancers

[View all](#) 



[Dr. Janjigian's Office Information](#) 



Languages: English

Request an Appointment

Our Care Advisors can answer many of your questions. They will connect you with the best healthcare provider for your needs.

Call 646-497-9053

[Make an appointment](#)

About Me

What I Do at MSK

- Chief, Gastrointestinal Oncology Service

Get To Know Me

I am a medical oncologist who cares for people with cancers of the gastrointestinal (GI) tract. My clinical practice and research are focused on improving outcomes for people with [esophageal](#) and [stomach cancers](#).

When patients first meet with me, they are often scared and have many questions. They usually want to know about their treatment options, chances for survival, and how their quality of life will be affected. I take the time to answer their questions clearly and honestly. My goal is to work with them to create the best possible care plan for their specific needs and preferences. I want my patients to leave our consultation feeling confident that they are in good hands.

As Chief of the Gastrointestinal Oncology Service at Memorial Sloan Kettering Cancer Center (MSK), I lead a dedicated team of experienced and compassionate physicians. My mission is to encourage research and the development of new therapies to help patients worldwide.

My Role at MSK

A gastrointestinal (GAS-troh-in-TES-tih-nul) oncologist is a cancer doctor with special training in the gastrointestinal (GI) system. This includes anal, colorectal, esophageal, gastric (stomach), liver, and pancreatic cancers, as well as GI stromal tumors and neuroendocrine tumors.

Areas of Expertise

My Specialties

Gastrointestinal Malignancies
New Chemotherapies
Esophageal and Gastric Cancers

Education & Honors

Education

MD, New York University School of Medicine

Residencies

Fellowships

Hematology/Oncology - Memorial Sloan Kettering Cancer Center

Board Certifications

Internal Medicine

Medical Oncology

Insurance Information

Understanding your insurance options is an important part of managing your cancer care. We have relationships with many common healthcare providers and plans.

Don't see your carrier or plan? [We can help you understand your coverage.](#)

If you don't have health insurance or are worried that your care may not be fully covered, our [financial assistance](#) programs may be able to help.

If you have questions about insurance, call us at [646-497-9176](tel:646-497-9176).

Make an Appointment



New Patients

Scheduling an appointment is easy. Click or call [646-497-9053](tel:646-497-9053)— we’re available Monday through Friday, 8 a.m. to 6 p.m. (Eastern time)

[Make an Appointment](#)

Current Patients

Request an appointment by logging on to MyMSK or calling your doctor's office. If you aren't registered for MyMSK, call [646-227-2593](tel:646-227-2593) for your Enrollment ID.

Contact and Location

Dr. Janjigian sees patients at one location.


Office Phone

 [646-888-4186](tel:646-888-4186)

Location

 New York, NY

[Rockefeller Outpatient Pavilion](#)

 160 East 53rd Street
New York, NY 10022

[Get Directions](#)

Looking to see a doctor at a different location? [See all MSK locations.](#)

Colleagues

Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.

[See all Gastrointestinal Oncology Service doctors](#) 

Clinical Trials

Clinical Trials Investigated by Dr. Janjigian

[A Phase 2 Study of AgenT-797 Plus Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancers](#)


[A Phase 2 Study of Pembrolizumab Immunotherapy With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer](#)

[A Phase 3 Study of Domvanalimab, Zimberelimab, and Chemotherapy Versus Nivolumab and Chemotherapy in People with Previously Untreated Inoperable or Metastatic Stomach, Gastroesophageal Junction, or Esophageal Cancer](#)

[A Phase I Study of TST001 in People with Locally Advanced or Metastatic Digestive Cancers](#)

Read more

+



Find a Clinical Trial for You

Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.

You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.

[Search clinical trials](#) →

Research and Publications

Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, Wyrwicz L, Yamaguchi K, Skoczylas T, Campos Bragagnoli A, Liu T, Schenker M, Yanez P, Tehfe M, Kowalyszyn R, Karamouzis MV, Bruges R, Zander T, Pazo-Cid R, Hitre E, Feeney K, Cleary JM, Poulart V, Cullen D, Lei M, Xiao H, Kondo K, Li M, Ajani JA. [First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma \(CheckMate 649\): a randomised, open-label, phase 3 trial](#). *Lancet*. 2021 Jul 3;398(10294):27-40. doi: 10.1016/S0140-6736(21)00797-2. Epub 2021 Jun 5. PMID: 34102137; PMCID: PMC8436782.

Janjigian YY, Kawazoe A, Yañez P, Li N, Lonardi S, Kolesnik O, Barajas O, Bai Y, Shen L, Tang Y, Wyrwicz LS, Xu J, Shitara K, Qin S, Van Cutsem E, Tabernero J, Li L, Shah S, Bhagia P, Chung HC. [The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer](#). *Nature*. 2021 Dec;600(7890):727-730. doi: 10.1038/s41586-021-04161-3. Epub 2021 Dec 15. PMID: 34912120; PMCID: PMC8959470.

Shitara K, Ajani JA, Moehler M, Garrido M, Gallardo C, Shen L, Yamaguchi K, Wyrwicz L, Skoczylas T, Bragagnoli AC, Liu T, Tehfe M, Elimova E, Bruges R, Zander T, de Azevedo S, Kowalyszyn R, Pazo-Cid R, Schenker M, Cleary JM, Yanez P, Feeney K, Karamouzis MV, Poulart V, Lei M, Xiao H, Kondo K, Li M, Janjigian YY. [Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer](#). *Nature*. 2022 Mar;603(7903):942-948. doi: 10.1038/s41586-022-04508-4. Epub 2022 Mar 23. PMID: 35322232; PMCID: PMC8967713.

Read more



Publications on PubMed

Visit PubMed for a full listing of Dr. Janjigian's journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.

[See all on PubMed](#) →

Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report ("disclose") the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Yelena Y. Janjigian discloses the following relationships and financial interests:

AbbVie

Professional Services and Activities

Agence Unik

Professional Services and Activities

American Association for Cancer Research

Professional Services and Activities

Arcus Biosciences, Inc.

Professional Services and Activities

AskGene Pharma, Inc.

Professional Services and Activities (Uncompensated)

Astellas

Professional Services and Activities

AstraZeneca

Professional Services and Activities

Bayer

Professional Services and Activities

Bristol-Myers Squibb

Professional Services and Activities

Canadian Gastric Cancer Association

Professional Services and Activities

Clinical Care Options

Professional Services and Activities

Daiichi Sankyo

Professional Services and Activities

GlaxoSmithKline

Professional Services and Activities

Guardant Health, Inc.

Professional Services and Activities

Mayo Clinic

Professional Services and Activities

Merck & Co Inc.

Professional Services and Activities

PeerView Institute for Medical Education (PVI)

Professional Services and Activities

PlatformQ Health Education

Professional Services and Activities

Research to Practice

Professional Services and Activities

Rgenix

Equity

If you're a patient at MSK and would like more information about your doctor's external relationships, please talk with your doctor.

The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2022 through disclosure submission in spring 2023). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK's COI policies [here](#). For questions regarding MSK's COI-related policies and procedures, email MSK's Compliance Office at ecoi@mskcc.org.

[View all disclosures](#) →

▾ Connect

[Contact us](#)

[Locations](#)

APPOINTMENTS

[800-525-2225](#)



▾ About MSK

[About us](#)

[Careers](#) 

[Giving](#) 

▾ Cancer Care

[Adult cancer types](#)

[Child & teen cancer types](#)

[Integrative medicine](#)

[Nutrition & cancer](#)

[Find a doctor](#)

▾ Research & Education

[Sloan Kettering Institute](#)

[Gerstner Sloan Kettering Graduate School](#) 

[Graduate medical education](#)

[MSK Library](#) 

[Communication preferences](#)

[Cookie preferences](#)

[Legal disclaimer](#)

[Accessibility statement](#)

[Privacy policy](#)

[Price transparency](#)

[Public notices](#)

© 2024 Memorial Sloan Kettering Cancer Center